Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $612 from $596 and keeps an Overweight rating on the shares. The firm adjusted models among its biopharma coverage for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting from the group.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $543 from $541 at RBC Capital
- Halozyme enters global global collaboration and license agreement with Vertex
- Anthropic Finalizes $400 Million Takeover of AI Startup Coefficient Bio
- Vertex announces U.S. FDA approval for label extensions of Alyftrek, Trikafta
- Vertex Advances FDA Filing for IgA Nephropathy Therapy